Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.77 |
| ▸ | MAOB | P27338 | 9/20 | 0.69 |
| ▸ | P4HB | P07237 | 1/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365331 | 1.00 | NFKB1 (0.77) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL82267 | 1.00 | NFKB1 (0.77) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL8055837 | 1.00 | NFKB1 (0.77) | NFKB1MAOBP4HBABCG2MAOA | |
| Hydrochloric Acid SCHEMBL6821798 | 0.98 | NFKB1 (0.74) | NFKB1MAOBP4HBABCG2MAOA | |
| Guanidine SCHEMBL8060785 | 0.91 | NFKB1 (0.64) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL6662586 | 0.88 | NFKB1 (0.65) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL7499883 | 0.88 | NFKB1 (0.60) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL5598947 | 0.87 | NFKB1 (1.00) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL5598951 | 0.87 | NFKB1 (1.00) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL8634363 | 0.86 | NFKB1 (0.58) | NFKB1MAOBP4HBABCG2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| CN-119371372-A | Bcr-Abl targeting molecular gel and preparation method and application thereof | 中山大学 | 2025-01-28 | — | — | CN | claimed |
| WO-2024167565-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | PURDUE RESEARCH FOUNDATION (US) | 2024-08-15 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20180105492-A1 | COMPOUNDS DERIVED FROM 3-ALKYLAMINE-1H-INDOLYL ACRYLATE AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (ES) | 2018-04-19 | — | — | US | claimed |
| EP-3208262-A1 | COMPOUNDS DERIVED FROM 3-ALKYLAMINO-1H-INDOLE ACRYLATE, AND THE USE THEREOF IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Fundación Para La Investigación Biomédica Del Hospital De La Princesa (ES) | 2017-08-23 | — | — | EP | claimed |
| EP-1526584-B1 | Method of forming electroluminescent semiconducting nanocrystal patterned layer for an organic-inorganic hybrid electroluminescent devices, and organic-inorganic hybrid electroluminescent device using the same. | SAMSUNG ELECTRONICS CO LTD (KR) | 2017-06-14 | — | — | EP | claimed |
| EP-1429768-B1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA (DE) | 2016-11-16 | — | — | EP | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050161666-A1 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2005-07-28 | — | — | US | claimed |
| US-6919325-B2 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-07-19 | — | — | US | claimed |
| US-6916890-B1 | Thermally reworkable epoxy resins and compositions based thereon | HENKEL CORPORATION (US) | 2005-07-12 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| EP-1526584-A2 | Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same | Samsung Electronics Co., Ltd (KR) | 2005-04-27 | — | — | EP | claimed |
| EP-1429768-A1 | NOVEL MEDICAMENTS FOR INHALATION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-06-23 | — | — | EP | claimed |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | claimed |
| WO-2003031492-A1 | THERMALLY REWORKABLE EPOXY RESINS AND COMPOSITIONS BASED THEREO N | HENKEL CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| WO-2003024452-A1 | NOVEL MEDICAMENTS FOR INHALATION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | NFKB1 3303/4885MAOB 1491/4885P4HB 698/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | NFKB1 3303/4885MAOB 1491/4885P4HB 698/4885 |
| US-20180105492-A1 | COMPOUNDS DERIVED FROM 3-ALKYLAMINE-1H-INDOLYL ACRYLATE AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NFE2L2, KEAP1, HTT | NFKB1 339/4885MAOB 568/4885P4HB 2954/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | NFKB1 677/4885MAOB 1285/4885P4HB 1168/4885 |
| US-20030130300-A1 | Respiratory system disorders; synergistic mixtures | ADRB3, ADRB1, CHRM3 | NFKB1 459/4885MAOB 767/4885P4HB 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.